| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7838531 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Jul, 2024
(3 months from now) | |
| US8828356 | EIGER BIOPHARMS | Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis |
Oct, 2024
(5 months from now) | |
Zokinvy is owned by Eiger Biopharms.
Zokinvy contains Lonafarnib.
Zokinvy has a total of 2 drug patents out of which 0 drug patents have expired.
Zokinvy was authorised for market use on 20 November, 2020.
Zokinvy is available in capsule;oral dosage forms.
Zokinvy can be used as reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps).
Drug patent challenges can be filed against Zokinvy from 20 November, 2024.
The generics of Zokinvy are possible to be released after 20 November, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-324) | Nov 20, 2027 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2025 |
Drugs and Companies using LONAFARNIB ingredient
NCE-1 date: 20 November, 2024
Market Authorisation Date: 20 November, 2020
Treatment: Reducing the risk of mortality in hutchinson-gilford progeria syndrome (hgps)
Dosage: CAPSULE;ORAL
ZOKINVY family patents
